A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer - A single institute study

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1879-1887

  Nio, Yoshinori ^a,b   Koike, Makoto ^a   Omori, Hiroshi ^a   Hashimoto, Koji ^a   Itakura, Masayuki ^a   Yano, Seiji ^a   Higami, Tetsuya ^a   Maruyama, Riruke ^b  

^a Dept of Cardiovasc/Digest Surg ^*  (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Gastric cancer; Neoadjuvant chemotherapy; Randomized consent design trial; UFT

Indexed keywords

TEGAFUR; UFT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BLEEDING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HISTOLOGY; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INFORMED CONSENT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 3242683562     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wilke H, Preusser U, Fink U, Gunzer U, Meyer HJ, Meyer J et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7: 1318-26, 1989.
2. Ajani J, Mayer R and Dm O: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 85: 1839-44, 1993.
3. Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M et al: Neoadjuvant chemotherapy in locally advanced gastric carcinoma - a phase II trial with combined intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 30A: 1269-75, 1994.
4. Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ et al: Preoperative chemotherapy for stage III - IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 82: 1248-52, 1995.
5. Gallardo-Rincon D, Onate-Ocana L and Calderillo-Ruiz G: Neoadjuvant chemotherapy with P-ELF (cisplatin, etposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: A phase II study. Ann Surg Oncol 7: 45-50, 2000.
6. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P and Ajani JA: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229: 303-8, 1999.
7. Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S et al: Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17: 256-61, 1993.
8. Kang Y, Choi D, Im Y, Kim C, Lee J, Moon N et al: A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proc Ann Meet Am Soc Clin Oncol 15: A503, 1996.
9. Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA et al: Chemotherapy for operable gastric cancer: results of the Dutch randomized FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 35: 558-62, 1999.
10. Kawaura Y, Ohmura K, Hashizume Y, Takayama K, Sakatoku M, Hirano M et al: Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer. Jpn J Cancer Chemother 12: 348-52, 1985.
11. Fujimoto S, Miyazaki M, Endoh F, Shimura T, Sugasawa H, Takahashi O et al: Preoperative cancer chemotherapy for gastric cancer. Jpn J Cancer Chemother 12: 1010-18, 1985.
12. Ohmori Y, Kajitani T, Akiyama H, Abe O, Kusama S, Sakakibara N et al: Study of pre- and post-operative chemotherapy with oral 5-FU in patients with gastric cancer. Jpn J Cancer Chemother 20: 1781-9, 1993.
13. Arima S, Ohsato K, Hisatsugu T and Shimura H: Multicenter randomized study of adjuvant chemotherapy with mitomycin-C and tegafur or tegafur-uracil in gastric cancer. Eur J Surg 160: 227-32, 1994.
14. Ota K, Taguchi T and Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333-8, 1988.
15. Zelen M: A new design for randomized clinical trials. N Engl J Med 300: 1242-5, 1979.
16. Nio Y, Sato Y, Nagami H, Teramoto M, Inoue Y, Yano S et al: Neoadjuvant chemotherapy of gastric cancer with oral UFT (a mixture of uracil and futrafur) during the waiting period for surgery. Anticancer Res 18: 523-30, 1998.
17. Nio Y, Iguchi C, Yamasawa K, Itakura M, Omori H, Hashimoto K et al: Oral UFT (uracil plus futrafur) for neoadjuvant chemotherapy of gastric cancer. Gastric Cancer 2: 64-73, 1999.
18. Schoenfeld DA and Richter JR: Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38: 163-70, 1982.
19. TNM Classification of Malignant Tumours. Fifth Edition. International Union Against Cancer. A John Wiley & Sons, Inc., Publication. 1997.
20. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-14, 1981.
21. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer 1: 10-24, 1998.
22. Nio Y, Tseng CC, Shiraishi T, Tsubono M, Kawabata K, Masai Y et al: A phase II study of 5-fluorouracil, cisplatin and 4′-epirubicin (FPEPIR) in the treatment of advanced solid cancers. Am J Clin Oncol 16: 96-101, 1993.
23. Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC): Tobe T, Nio Y, Tseng CC, Shiraishi T, Tsubono M, Kawabata K et al: A randomized, comparative study of combination chemotherapies in advanced gastric cancers: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4′-epirubicin (FPEPIR). Anticancer Res 12: 1983-8, 1992.
24. Kim YH, Shin SW, Kim BS, Park YT, Kim JG and Kim JS: A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. Oncology (Huntingt) 11(Suppl 10): 119-23, 1997.
25. Ravaud A, Borner M, Schellens JH, Geoffrois L, Schoffski P, Wanders J et al: UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer. Oncology (Huntingt) 13(Suppl 3): 61-3, 1999.
26. Jeen YT, Yoon SY, Shin SW, Kim BS, Mok YJ, Kim CS et al: Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 91: 2288-93, 2001.
27. Roder JD, Bottcher K, Busch R, Wittekind C, Hermanek P and Siewert JR: Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 82: 621-31, 1998.
28. Karpeh MS, Leon L, Klimstra D and Brennan MF: Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg 232: 362-71, 2000.
29. Doglietto GB, Pacelli F, Caprino P, Sgadari A and Crucitti F: Surgery: independent prognostic factor in curable and far advanced gastric cancer. World J Surg 24: 459-63, 2000.
30. Kikuchi S, Sakakibara Y, Sakuramoto S, Kobayashi N, Shimao H, Mieno H et al: Recent results in the surgical treatment of gastric cancer according to the Japanese and TNM classification. Anticancer Res 21: 3589-93, 2001.